CALYPSO
MEDI4736 Combinations in Metastatic Renal Cell Carcinoma
- NCT02819596 ↗
- Completed
- Queen Mary University of London
- Deep
We haven't built an HCP commentary report on CALYPSO (savolitinib plus durvalumab; durvalumab plus tremelimumab; savolitinib in metastatic clear cell and papillary renal cell carcinoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Questions raised in the commentary
Automated from the 40 newest of 48 indexed sources (Feb 2023 – Oct 2026). Each question is raised in at least two. Not an Erudio report: no source links. Not medical advice.
- Whether MET status identifies patients who benefit from savolitinib plus durvalumab
- Whether ctDNA can serve as a clinically useful prognostic biomarker in papillary disease
- Whether PD-L1 or other biomarkers can guide treatment selection
Also discussed: papillary RCC treatment landscape.
Indexed commentary on CALYPSO so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 28 | |
| YouTube | 13 | |
| Podcasts | 7 |
The trial
ClinicalTrials.gov- Official title
- MEDI4736 Combinations in Metastatic Renal Cell Carcinoma
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Renal Clear Cell Carcinoma; Renal Papillary Cell Carcinoma
- Interventions
- Savolitinib; MEDI4736; Tremelimumab
- Arms
- Savolitinib · Experimental
- MEDI4736 · Experimental
- Savolitinib and MEDI4736 · Experimental
- Tremelimumab and MEDI4736 · Experimental
- Enrollment
- 69
- Primary outcomes
- Identify Dose Limiting Toxicity -Phase Ib
- Overall response (OR) in patients with metastatic clear cell renal cancer
- Overall response (OR) in patients with metastatic Papillary cell renal cancer
- Overall response (OR)in patients with metastatic renal cell cancer -Biomarker enrichment phase
- Sponsor
- Queen Mary University of London with Vall d'Hebron Institute of Oncology, AstraZeneca
- Start
- May 3, 2016
- Primary completion
- Jul 17, 2024
- Results posted
- No
- Registry record
- NCT02819596 · updated Nov 4, 2024
Publications
linked from the registry- Powles T et al. CALYPSO: A three-arm randomized phase II study of durvalumab alone or with savolitinib or tremelimumab in previously treated advanced clear cell renal cancer. Journal of Clinical Oncology 40, no. 17_suppl (June 10, 2022) LBA4503-LBA4503
- Suarez C, Larkin JMG, Patel P, Valderrama BP, Rodriguez-Vida A, Glen H, Thistlethwaite F, Ralph C, Srinivasan G, Mendez-Vidal MJ, Hartmaier R, Markovets A, Prendergast A, Szabados B, Mousa K, Powles T. Phase II Study Investigating the Safety and Efficacy of Savolitinib and Durvalumab in Metastatic Papillary Renal Cancer (CALYPSO). J Clin Oncol. 2023 May 10;41(14):2493-2502. doi: 10.1200/JCO.22.01414. Epub 2023 Feb 21. PubMed 36809050
- Suarez Rodriguez et al. Overall survival results for durvalumab and savolitinib in metastatic papillary renal cancer. Journal of Clinical Oncology 2020 38:6_suppl, 619-619.
- Suarez Rodriguez et al Clinical activity of durvalumab and savolitinib in MET-driven, metastatic papillary renal cancer. J Clin Oncol 39, 2021 (suppl 15; abstr 4511).
- Jackson-Spence F, Larkin J, Patel P, Valderrama BP, Rodriguez-Vida A, Glen H, Thistlethwaite FC, Ralph C, Srinivasan G, Mendez-Vidal MJ, Childress M, Li W, Boyle P, Gasco A, Markovets A, Hartmaier R, Ackerman C, Szabados BE, Priyadarshini G, Jamal F, Powles T, Suarez C. CALYPSO: Final Results of Savolitinib and Durvalumab Combination in Metastatic Papillary Renal Cancer. J Clin Oncol. 2026 Apr 20;44(12):1076-1082. doi: 10.1200/JCO-25-01840. Epub 2026 Mar 20. PubMed 41861260